Jacqueline Wright

October 17, 2026

BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.

October 4, 2026

Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.

October 17, 2026

nVent partners with AMD on cooling; RBC raises target. nVent Electric announced a collaboration with AMD to develop cooling solutions for the Helios Rackscale system. This partnership targets the growing data center infrastructure market. Separately, RBC Capital raised its price target to $208 while maintaining an Outperform rating. The company is scheduled to report third-quarter financial results on October 30.